Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy. 2022

Sunati Sahoo, and Gregor Krings, and Yunn-Yi Chen, and Jodi M Carter, and Beiyun Chen, and Hua Guo, and Hanina Hibshoosh, and Emily Reisenbichler, and Fang Fan, and Shi Wei, and Laila Khazai, and Ronald Balassanian, and Molly E Klein, and Sonal Shad, and Sara J Venters, and Alexander D Borowsky, and W Fraser Symmans, and I Tolgay Ocal
From the Department of Pathology, UTSW Medical Center, Dallas, Texas (Sahoo).

Neoadjuvant systemic therapy refers to the use of systemic agent(s) for malignancy prior to surgical treatment and has recently emerged as an option for most breast cancer patients eligible for adjuvant systemic therapy. Consequently, treated breast carcinomas have become routine specimens in pathology practices. A standard protocol has not yet been universally adopted for the evaluation and reporting of these specimens. The American Joint Committee on Cancer staging system recognizes the challenges in staging breast carcinomas after neoadjuvant treatment and provides important data points but does not currently provide detailed guidance in estimating the residual tumor burden in the breast and lymph nodes. The Residual Cancer Burden system is the only Web-based system that quantifies treatment response as a continuous variable using residual tumor burden in the breast and the lymph nodes. To provide clarifications and guidance for evaluation and reporting of postneoadjuvant breast specimens, discuss issues with the current staging and reporting systems, and provide specific suggestions for future modifications to the American Joint Committee on Cancer system and the Residual Cancer Burden calculator. English-language literature on the subject and the data from the I-SPY 2, a multicenter, adaptive randomization phase 2 neoadjuvant platform trial for early-stage, high-risk breast cancer patients. This article highlights challenges in the pathologic evaluation and reporting of treated breast carcinomas and provides recommendations and clarifications for pathologists and clinicians. It also provides specific recommendations for staging and discusses future directions.

UI MeSH Term Description Entries
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D001940 Breast In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES. Breasts
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D017024 Chemotherapy, Adjuvant Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment. Adjuvant Chemotherapy,Drug Therapy, Adjuvant,Adjuvant Drug Therapy
D018365 Neoplasm, Residual Remnant of a tumor or cancer after primary, potentially curative therapy. Minimal Residual Disease,Residual Cancer,Residual Tumor,Minimal Disease, Residual,Residual Disease, Minimal,Residual Neoplasm,Residual Tumour,Cancer, Residual,Minimal Residual Diseases,Residual Cancers,Residual Minimal Disease,Residual Minimal Diseases,Residual Neoplasms,Residual Tumors,Residual Tumours,Tumour, Residual
D020360 Neoadjuvant Therapy Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy. Neoadjuvant Chemoradiation,Neoadjuvant Chemoradiation Therapy,Neoadjuvant Chemoradiation Treatment,Neoadjuvant Chemoradiotherapy,Neoadjuvant Chemotherapy,Neoadjuvant Chemotherapy Treatment,Neoadjuvant Radiation,Neoadjuvant Radiation Therapy,Neoadjuvant Radiation Treatment,Neoadjuvant Radiotherapy,Neoadjuvant Systemic Therapy,Neoadjuvant Systemic Treatment,Neoadjuvant Treatment,Chemoradiation Therapy, Neoadjuvant,Chemoradiation Treatment, Neoadjuvant,Chemoradiation, Neoadjuvant,Chemoradiotherapy, Neoadjuvant,Chemotherapy Treatment, Neoadjuvant,Chemotherapy, Neoadjuvant,Neoadjuvant Chemoradiation Therapies,Neoadjuvant Chemoradiation Treatments,Neoadjuvant Chemoradiations,Neoadjuvant Chemoradiotherapies,Neoadjuvant Chemotherapies,Neoadjuvant Chemotherapy Treatments,Neoadjuvant Radiation Therapies,Neoadjuvant Radiation Treatments,Neoadjuvant Radiations,Neoadjuvant Radiotherapies,Neoadjuvant Systemic Therapies,Neoadjuvant Systemic Treatments,Neoadjuvant Therapies,Neoadjuvant Treatments,Radiation Therapy, Neoadjuvant,Radiation Treatment, Neoadjuvant,Radiation, Neoadjuvant,Radiotherapy, Neoadjuvant,Systemic Therapy, Neoadjuvant,Systemic Treatment, Neoadjuvant,Therapy, Neoadjuvant,Therapy, Neoadjuvant Chemoradiation,Therapy, Neoadjuvant Radiation,Therapy, Neoadjuvant Systemic,Treatment, Neoadjuvant,Treatment, Neoadjuvant Chemoradiation,Treatment, Neoadjuvant Chemotherapy,Treatment, Neoadjuvant Radiation,Treatment, Neoadjuvant Systemic

Related Publications

Sunati Sahoo, and Gregor Krings, and Yunn-Yi Chen, and Jodi M Carter, and Beiyun Chen, and Hua Guo, and Hanina Hibshoosh, and Emily Reisenbichler, and Fang Fan, and Shi Wei, and Laila Khazai, and Ronald Balassanian, and Molly E Klein, and Sonal Shad, and Sara J Venters, and Alexander D Borowsky, and W Fraser Symmans, and I Tolgay Ocal
January 2009, Zhonghua bing li xue za zhi = Chinese journal of pathology,
Sunati Sahoo, and Gregor Krings, and Yunn-Yi Chen, and Jodi M Carter, and Beiyun Chen, and Hua Guo, and Hanina Hibshoosh, and Emily Reisenbichler, and Fang Fan, and Shi Wei, and Laila Khazai, and Ronald Balassanian, and Molly E Klein, and Sonal Shad, and Sara J Venters, and Alexander D Borowsky, and W Fraser Symmans, and I Tolgay Ocal
June 2010, Journal de radiologie,
Sunati Sahoo, and Gregor Krings, and Yunn-Yi Chen, and Jodi M Carter, and Beiyun Chen, and Hua Guo, and Hanina Hibshoosh, and Emily Reisenbichler, and Fang Fan, and Shi Wei, and Laila Khazai, and Ronald Balassanian, and Molly E Klein, and Sonal Shad, and Sara J Venters, and Alexander D Borowsky, and W Fraser Symmans, and I Tolgay Ocal
May 2016, Journal of pathology and translational medicine,
Sunati Sahoo, and Gregor Krings, and Yunn-Yi Chen, and Jodi M Carter, and Beiyun Chen, and Hua Guo, and Hanina Hibshoosh, and Emily Reisenbichler, and Fang Fan, and Shi Wei, and Laila Khazai, and Ronald Balassanian, and Molly E Klein, and Sonal Shad, and Sara J Venters, and Alexander D Borowsky, and W Fraser Symmans, and I Tolgay Ocal
July 2012, Applied immunohistochemistry & molecular morphology : AIMM,
Sunati Sahoo, and Gregor Krings, and Yunn-Yi Chen, and Jodi M Carter, and Beiyun Chen, and Hua Guo, and Hanina Hibshoosh, and Emily Reisenbichler, and Fang Fan, and Shi Wei, and Laila Khazai, and Ronald Balassanian, and Molly E Klein, and Sonal Shad, and Sara J Venters, and Alexander D Borowsky, and W Fraser Symmans, and I Tolgay Ocal
February 2022, Pathology, research and practice,
Sunati Sahoo, and Gregor Krings, and Yunn-Yi Chen, and Jodi M Carter, and Beiyun Chen, and Hua Guo, and Hanina Hibshoosh, and Emily Reisenbichler, and Fang Fan, and Shi Wei, and Laila Khazai, and Ronald Balassanian, and Molly E Klein, and Sonal Shad, and Sara J Venters, and Alexander D Borowsky, and W Fraser Symmans, and I Tolgay Ocal
August 2019, Breast cancer research and treatment,
Sunati Sahoo, and Gregor Krings, and Yunn-Yi Chen, and Jodi M Carter, and Beiyun Chen, and Hua Guo, and Hanina Hibshoosh, and Emily Reisenbichler, and Fang Fan, and Shi Wei, and Laila Khazai, and Ronald Balassanian, and Molly E Klein, and Sonal Shad, and Sara J Venters, and Alexander D Borowsky, and W Fraser Symmans, and I Tolgay Ocal
February 2013, Anti-cancer agents in medicinal chemistry,
Sunati Sahoo, and Gregor Krings, and Yunn-Yi Chen, and Jodi M Carter, and Beiyun Chen, and Hua Guo, and Hanina Hibshoosh, and Emily Reisenbichler, and Fang Fan, and Shi Wei, and Laila Khazai, and Ronald Balassanian, and Molly E Klein, and Sonal Shad, and Sara J Venters, and Alexander D Borowsky, and W Fraser Symmans, and I Tolgay Ocal
February 1996, Radiology,
Sunati Sahoo, and Gregor Krings, and Yunn-Yi Chen, and Jodi M Carter, and Beiyun Chen, and Hua Guo, and Hanina Hibshoosh, and Emily Reisenbichler, and Fang Fan, and Shi Wei, and Laila Khazai, and Ronald Balassanian, and Molly E Klein, and Sonal Shad, and Sara J Venters, and Alexander D Borowsky, and W Fraser Symmans, and I Tolgay Ocal
February 2020, Clinical breast cancer,
Sunati Sahoo, and Gregor Krings, and Yunn-Yi Chen, and Jodi M Carter, and Beiyun Chen, and Hua Guo, and Hanina Hibshoosh, and Emily Reisenbichler, and Fang Fan, and Shi Wei, and Laila Khazai, and Ronald Balassanian, and Molly E Klein, and Sonal Shad, and Sara J Venters, and Alexander D Borowsky, and W Fraser Symmans, and I Tolgay Ocal
January 2006, Annals of clinical and laboratory science,
Copied contents to your clipboard!